NASDAQ
2.17USD
-0.06 (-2.69%)
We have scored 8 news catalysts on Atossa Therapeutics, Inc. (ATOS) over the past 12 months. The biggest single-day move next to one of them came Jun 11, 2026, when ATOS closed −41.1%: “Dow Jumps Over 250 Points; US Initial Jobless Claims Rise”. Coverage across the window leans positive (average ticker sentiment +0.35). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
21.7M
P/E
—
EPS
—
Beta
1.27
52W range
1.7-14.85
Day range
2.15–2.25
Open
2.25
Prev close
2.23
Volume
32.2K
Avg volume
85.4K
Dividend
0.00
IPO
2012-11-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Atossa Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ATOS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
